Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma

Inclusion Criteria:

A histologically established diagnosis of multiple myeloma with evidence of relapse or refractory disease.
Must have a detectable serum or urine M-Protein by protein electrophoresis that is at least 500 mg/dL (serum) or 1 gm/24 hours (urine), respectively, or serum free light chain level >100 mg/l for the involved free light chain.
Must have received at least one (1) prior line of systemic treatment that has included either lenalidomide or thalidomide.
Must be willing to provide correlative blood samples.

Exclusion Criteria:

Must not have received an excessive cumulative dose of anthracycline
No ≥ grade 2 peripheral neuropathy.
No cytotoxic chemotherapy within 30 days prior to registration for protocol therapy.
No autologous stem cell transplant within 6 months prior to registration for protocol therapy
No prior radiation therapy to > 25% of bone marrow forming bones (i.e., pelvis) within 30 days prior to registration for protocol therapy. See Study Procedures Manual to calculate percent of prior radiation.
No current corticosteroid therapy in doses greater than 10 mg daily of prednisone (or equivalent) if given for management of co-morbid conditions.
No known central nervous system involvement by myeloma.
No poorly controlled intercurrent illness including, but not limited to, ongoing or active infection, poorly controlled diabetes, symptomatic congestive heart failure, cardiac arrhythmia, or psychiatric illness/social climate that in the opinion of the investigator would limit compliance with study requirements.
No patients known to be positive for HIV, or active Hepatitis A, B, or C.
No major surgery within 30 days prior to registration for protocol therapy. Placement of a venous access device within 30 days prior to registration for protocol therapy is allowed.